@article{TCR8810,
author = {Yusuke Inoue and Murat Osman and Takafumi Suda and Haruhiko Sugimura},
title = {PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 2},
year = {2016},
keywords = {},
abstract = {Immune checkpoint blockade has emerged as a promising and distinct treatment strategy and has caused a paradigm shift in oncology. Significant response and survival benefit have been observed in a fraction of patients who were treated with immune checkpoint inhibitors (ICIs) in several malignancies including melanoma (1-3), non-small-cell lung cancer (NSCLC) (4-7), gastric cancer (8), urothelial carcinoma (9), Hodgkin’s lymphoma (10), and head and neck squamous cell carcinoma (11).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/8810}
}